Individual investors represent 42% of the ownership of CSPC Pharmaceutical Group Limited (HKG: 1093), while institutions represent 28%

A look at the shareholders of CSPC Pharmaceutical Group Limited (HKG: 1093) can tell us which group is more powerful. With 42% of the capital, individual investors hold the maximum number of shares in the company. That is, the group is most likely to benefit the most if the stock rises (or to lose the most if there is a decline).

Institutions, for their part, represent 28% of the company’s shareholders. Institutions often own shares in more established companies, while it is not uncommon to see insiders owning a good number of smaller companies.

Let’s take a closer look at each type of CSPC pharmaceutical group owner, starting with the table below.

Consult our latest analysis for the pharmaceutical group CSPC

SEHK: 1093 Distribution of ownership December 10, 2021

What does institutional ownership tell us about the pharmaceutical group CSPC?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it’s included in a major index. . We would expect most businesses to have some institutions listed, especially if they are growing.

The CSPC Pharmaceutical Group already has institutions registered in the share register. Indeed, they hold a respectable stake in the company. This suggests some credibility among professional investors. But we cannot rely on this fact alone because institutions sometimes make bad investments, like everyone else. If several institutions change their mind about a stock at the same time, you could see the stock price drop quickly. So it’s worth checking out the profit history of pharmaceutical group CSPC below. Of course, the future is what really matters.

profit and revenue growth
SEHK: 1093 Revenue and revenue growth on December 10, 2021

Hedge funds don’t have a lot of shares in CSPC Pharmaceutical Group. The company’s CEO, Dongchen Cai, is the largest shareholder with 23% of the shares outstanding. With 6.5% and 6.1% of shares outstanding, respectively, UBS Asset Management and Common Success International Limited are the second and third shareholders.

Looking at the register of shareholders, we can see that 50% of the property is controlled by the 12 major shareholders, which means that no shareholder has a controlling interest in the property.

Institutional ownership research is a good way to assess and filter the expected performance of a stock. The same can be achieved by studying the feelings of analysts. Many analysts cover the stock, so it can be interesting to see what they are forecasting as well.

Insider property of the pharmaceutical group CSPC

The definition of business insiders can be subjective and vary from jurisdiction to jurisdiction. Our data reflects individual insiders, capturing at least board members. The management of the company manages the company, but the CEO will report to the board of directors, even if he is a member of the board.

Insider ownership is positive when it indicates that executives think like the real owners of the company. However, strong insider ownership can also confer immense power on a small group within the company. This can be negative in some circumstances.

It appears that insiders own a significant proportion of CSPC Pharmaceutical Group Limited. It is very interesting to see that the insiders have a significant HK $ 24 billion stake in this HK $ 103 billion company. It’s good to see this level of investment. You can check here if these insiders have bought recently.

General public property

The general public, generally individual investors, own 42% of the capital of CSPC Pharmaceutical Group. This size of ownership, while considerable, may not be enough to change company policy if the decision is not aligned with other large shareholders.

Owned by a private company

Our data indicates that private companies own 6.3% of the company’s shares. It is difficult to draw conclusions from this fact alone, so it is worth considering who owns these private companies. Sometimes insiders or other related parties have an interest in shares of a public company through a separate private company.

Next steps:

I find it very interesting to see who exactly owns a company. But to really understand better, we have to take other information into account as well.

I like to dive deeper on the performance of a company in the past. You can find the history of income and earnings in this detailed graphic.

But finally it’s the future, not the past, which will determine the success of the owners of this business. Therefore, we believe it is advisable to take a look at this free report showing whether analysts are predicting a better future.

NB: The figures in this article are calculated from data for the last twelve months, which refer to the 12-month period ending on the last date of the month of date of the financial statement. This may not be consistent with the figures in the annual report for the entire year.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St has no position in any of the stocks mentioned.

About Catherine Sherrill

Check Also

Shanghai Fosun Pharmaceutical: An announcement has just been posted by the issuer in the Chinese section of this website, a corresponding version of which may or may not be posted in this section

Shanghai Fosun Pharmaceutical : An announcement has just been published by the issuer in the …